stockportfolio.pro
Stocks / KRYS vs MASI
KRYS vs MASI
Krystal Biotech, Inc. and Masimo Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Krystal Biotech, Inc. (KRYS) | Masimo Corporation (MASI) | |
|---|---|---|
| Market cap | $9.2B | $9.4B |
| Revenue (latest FY) | $389.13M | $1.53B |
| Net income (latest FY) | $204.83M | $-151.50M |
| Revenue growth (5y CAGR) | — | 5.9% |
| Net margin | 52.6% | -9.9% |
| Return on equity | 16.8% | -21.0% |
| P/E ratio | 42.0 | 44.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open KRYS — free Open MASI — freeFrequently asked questions
Which is bigger, KRYS or MASI?
Masimo Corporation is larger by market capitalization — $9.4B versus $9.2B.
Which grows faster, KRYS or MASI?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.